MarketCap
Facebook
X
TelegramEyeGate Pharmaceuticals, Inc. EBITDA per Share 2011-2026 | EYEG
Annual EBITDA per Share EyeGate Pharmaceuticals, Inc.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.22 | - | 1.92 | 1.54 | 2.11 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.22 | 1.54 | 1.95 |
EBITDA per Share of other stocks in the Biotechnology industry
| Issuer | EBITDA per Share | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-15.2 | - | 2.43 % | $ 254 M |  Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-1.68 | $ 5.15 | 15.21 % | $ 12.4 B |  Australia |
 |
Allakos
ALLK
|
-2.19 | - | - | $ 28.6 M |  USA |
 |
AlloVir
ALVR
|
-3.02 | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
0.08 | - | - | $ 866 M |  China |
 |
Applied Molecular Transport
AMTI
|
-3.2 | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.75 | - | - | $ 40.3 B | USA |
 |
Applied Therapeutics
APLT
|
-0.77 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-0.92 | - | -39.0 % | $ 4.57 M | USA |
 |
Genfit SA
GNFT
|
-2.24 | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
-0.23 | - | -13.47 % | $ 169 M | France |
 |
Advaxis
ADXS
|
-5.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
-2.45 | - | 0.23 % | $ 488 M | USA |
 |
Midatech Pharma plc
MTP
|
-0.09 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Aligos Therapeutics
ALGS
|
-8.81 | $ 6.51 | -2.54 % | $ 64.4 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
3.68 | $ 22.92 | 0.17 % | $ 1.07 B | USA |
 |
Avenue Therapeutics
ATXI
|
-0.98 | - | -52.27 % | $ 4.45 M | USA |
 |
BioNTech SE
BNTX
|
62.6 | $ 105.19 | 2.21 % | $ 27.2 B | Germany |
 |
Aravive
ARAV
|
-1.92 | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
-2.69 | - | - | - |  Russia |
 |
Can-Fite BioPharma Ltd.
CANF
|
-6.03 | $ 3.0 | -1.32 % | $ 4.94 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
-0.08 | - | 5.93 % | $ 314 M |  Canada |
 |
AstraZeneca PLC
AZN
|
0.74 | - | - | $ 96.9 B | Britain |
 |
AgeX Therapeutics
AGE
|
-2.35 | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-1.05 | - | -2.5 % | $ 5.88 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-6.7 | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
0.1 | $ 1.43 | 1.78 % | $ 368 M | USA |
 |
BioDelivery Sciences International
BDSI
|
0.38 | - | -4.8 % | $ 255 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.42 | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
-0.36 | - | - | $ 26.5 M | USA |
 |
BeiGene, Ltd.
BGNE
|
0.42 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Aquestive Therapeutics
AQST
|
-0.66 | $ 4.24 | -1.85 % | $ 453 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-0.09 | $ 24.47 | -0.24 % | $ 3.11 B | USA |
 |
Burford Capital Limited
BUR
|
1.11 | $ 4.99 | 0.6 % | $ 804 M | Britain |
 |
AIkido Pharma
AIKI
|
-3.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-0.99 | $ 1.58 | -1.25 % | $ 420 M | Britain |
 |
Aptose Biosciences
APTO
|
0.01 | - | -45.71 % | $ 1.2 M | Canada |
 |
BioXcel Therapeutics
BTAI
|
-4.11 | $ 1.2 | 4.35 % | $ 14.6 M | USA |
 |
AVROBIO
AVRO
|
0.24 | - | 1083.1 % | $ 745 M | USA |
 |
Cabaletta Bio
CABA
|
-1.7 | $ 3.31 | -3.92 % | $ 333 M | USA |
 |
bluebird bio
BLUE
|
-1.97 | - | - | $ 546 M | USA |
 |
Fennec Pharmaceuticals
FENC
|
-0.22 | $ 6.73 | -0.88 % | $ 192 M | USA |
 |
Akero Therapeutics
AKRO
|
-4.25 | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
-2.22 | - | - | $ 867 M | Germany |
 |
CymaBay Therapeutics
CBAY
|
-0.95 | - | - | $ 3.45 B | USA |
 |
Cidara Therapeutics
CDTX
|
-27.7 | - | - | $ 1.41 B | USA |
 |
ChromaDex Corporation
CDXC
|
0.21 | - | -0.88 % | $ 598 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-0.696 | - | 3.16 % | $ 1.9 M | USA |
 |
ContraFect Corporation
CFRX
|
-124 | - | -5.16 % | $ 5.39 M | USA |